EGFR and non-small cell lung carcinoma: This diagnostic test detects deletions in exon 19 and substitution mutations of exon 21 in the epidermal growth factor receptor (EGFR) gene to identify patients with metastatic non-small cell lung cancer (NSCLC) who would be eligible for treatment with erlotinib [201].